Teva to sell US manufacturing plant
March 4, 2015Manufacturing and Production, Sales and Marketing G&W Laboratories, Pennsylvania, Teva
Teva Pharmaceutical has announced that it has signed an agreement to sell a US manufacturing facility to G&W Laboratories. The …
EU widens indications for Pfizer vaccine
March 4, 2015Research and Development, Sales and Marketing EC, EMA, Pfizer, pneumococcal polysaccharide conjugate vaccine, prevenar
Pfizer has gained approval from the European Commission which has signed off on an EMA decision to recommend Prevenar 13 …
New chief executive for Takeda
March 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actos, Millennium, Nycomed, Takeda, Yasuchika Hasegawa, christophe weber
Japanese pharma giant Takeda has added the title of chief executive to its representative director, president and chief operating officer …
Scottish reforms proven to work says SMC
March 4, 2015Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …
Finance director general for Department of Health retiring
March 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Department of Health, DoH, director general, finance, richard douglas
The Department of Health’s director general for finance and the NHS Richard Douglas is to retire at the end of …
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Boehringer chases approval for anti-Pradaxa drug
March 3, 2015Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab
Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …
Takeda expands in Singapore
March 3, 2015Manufacturing and Production Singapore, Takeda, biopolis, emerging markets, vaccines
Japanese pharma giant Takeda has set up new Singapore offices in the Biopolis biomedical complex with the aim of expanding …
Chiesi reprimanded again over Fostair drug
March 3, 2015Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair
Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
Premise Health senior joins Nashville Health Care Council
March 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing nashville health care council, premise health
US worksite health and patient engagement firm Premise Health has announced that its senior VP Beth Ratliff has been selected …
ZMapp trials start in Liberia
March 2, 2015Research and Development, Sales and Marketing Africa, Ebola, Mapp, Vaccine, liberia, zmapp
Clinical trials to test the safety and efficacy of the experimental Ebola vaccine ZMapp are underway in infected parts of …
Eisai launches Lenvima in US
March 2, 2015Sales and Marketing FDA, Japan, Lenvima, US, dtc, thyroid
Japanese firm Eisai has launched its new thyroid cancer offering Lenvima in the US, making it the first country in …
Three drugs put forward for EMA authorisation
March 2, 2015Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia
Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …
23andMe appoints privacy officer
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, kate black
US genetics testing firm 23andMe has appointed Kate Black as its privacy officer and corporate counsel.
Precision medicine: the future of cancer treatment?
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood
There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …
GSK and Novartis swap assets
March 1, 2015Research and Development, Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, akt, merger, oncology, vaccines
GlaxoSmithKline’s planned major assets swap with Novartis has completed today as was predicted last week. Both firms announced the overhaul …
New EU indication for Bayer and Regeneron eye drug
February 27, 2015Sales and Marketing Bayer, European Commission, Eylea, aflibercept
Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …
Ousted Sanofi boss finds role at PureTech
February 27, 2015Sales and Marketing Bayer, Sanofi, Viehbacher, baumann, brandicourt, pott, puretech
US science and technology R&D company PureTech has appointed the former Sanofi chief executive Christopher Viehbacher to its board. Viehbacher …
Actavis and AZ see FDA approval for ‘superbug’ drug
February 27, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, Avycaz, FDA, US, ceftazidime/avibactam
Actavis and AstraZeneca’s combo ‘superbug’ drug Avycaz has been shown the green light to treat patients with complicated intra-abdominal infections …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
